GLOW Peptide Stack: GHK-Cu, BPC-157 and TB-500 Explained

The GLOW peptide stack combines three compounds — GHK-Cu, BPC-157, and TB-500 — into a single regimen marketed for skin quality, tissue repair, and recovery. It is popular in aesthetic and regenerative practice circles, and it is frequently described online with confident claims about benefits and dosing. This article separates what each component's research actually supports from what is simply asserted, and explains where the stack stands with the FDA.

Everything known about GLOW is known at the level of its components. There is no published human trial of the combination.

What Is the GLOW Peptide Stack?

"GLOW" is a marketplace name for a three-peptide combination:

• GHK-Cu — the copper complex of the human tripeptide glycyl-histidyl-lysine
• BPC-157 — a 15-amino-acid fragment of a gastric protein called Body Protection Compound
• TB-500 — a seven-amino-acid fragment of thymosin β-4

The name is not defined by any monograph. Ratios, salt forms, and whether the peptides share a vial all vary between sources. A related four-peptide blend, KLOW, adds the anti-inflammatory tripeptide KPV.

The Rationale: Three Mechanisms, One Goal

The case for combining these three is that each is described as acting on a different step of repair and remodeling:

The logic is coherent on paper. What it lacks is a study showing the three together do more, or anything different, than each alone.

GLOW Peptide Benefits: Claimed vs Supported

Online descriptions of GLOW commonly list benefits such as smoother skin, faster recovery, better hair, and reduced inflammation. Here is how those claims map to published evidence:

The pattern is consistent: the best evidence belongs to topical GHK-Cu, and it weakens considerably for the injectable components and for the combination.

What the Research on Each Component Looks Like

GHK-Cu

GHK-Cu is endogenous — it occurs in human plasma and declines with age. Controlled and open-label topical studies have reported improvements in skin appearance, though effect sizes varied with formulation and several studies were industry-sponsored. Its gene-expression data, drawn from the Broad Institute's Connectivity Map, is broad but comes from cell culture. For the dose question specifically, see GHK-Cu dosage.

BPC-157

BPC-157's research is predominantly animal work. FDA's July 2026 briefing identified a single small exploratory trial in ulcerative colitis and no studies administering BPC-157 to humans by the oral, subcutaneous, nasal, or transdermal routes for that indication. Our BPC-157 clinical research review summarizes what exists.

TB-500

TB-500 is a fragment of thymosin β-4, and the two are not interchangeable in the literature. FDA found no medical literature in which TB-500 was given to patients. See the TB-500 mechanism overview for the underlying biology.

GLOW Peptide Dosage: What Can Honestly Be Said

People searching for a GLOW peptide dosage will find confident numbers online. None of them comes from a clinical trial of the blend, because none exists, and none is FDA-labeled. Those figures also cannot account for the fact that different GLOW products contain different amounts of each peptide.

Where a prescriber considers any component, dosing is prescriber-determined and should be reasoned from that component's own evidence and route. The TB-500 half-life and dosing reference and GHK-Cu dosage posts cover what is described for each. The peptide calculator handles reconstitution arithmetic; it does not recommend a dose.

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

Regulatory Status

At the July 23, 2026 PCAC meeting, FDA proposed that BPC-157 and TB-500 (free base and acetate) not be added to the 503A Bulks List, citing inadequate characterization and insufficient effectiveness and safety evidence. These were advisory-committee proposals rather than final rules; neither peptide was ever FDA-approved. Details: BPC-157 and the 503A decision and TB-500 and the 503A decision.

GHK-Cu followed a separate path and, as of the site's July 2026 tracker, was scheduled for PCAC review before February 2027. Because two of GLOW's three components face an unfavorable proposal, whether a 503A pharmacy can compound a GLOW-type preparation depends on current determinations — check the FDA peptide status tracker.

Safety Considerations

• Copper exposure. Systemic GHK-Cu is contraindicated in Wilson's disease; zinc balance is worth monitoring in chronic use. See GHK-Cu contraindications.
• Limited human safety data. FDA found insufficient human safety information for BPC-157 and TB-500.
• Immunogenicity. FDA flagged immunogenicity risk for injectable peptides from aggregation and impurities.
• Combined preparations. Stability and compatibility of the three peptides in one solution have not been characterized in the published literature.
• Gray-market products. "Research use only" vials are not compounded medications.

Where GLOW Fits

GLOW is best understood as a hypothesis built from three separately studied molecules, one of which — GHK-Cu — has meaningful clinical evidence for skin. For the wider picture of how peptides are used in skin care, start at the peptides for skin hub. Newtropin connects licensed providers with a licensed 503A compounding partner; providers can learn more on the provider pathway.

Frequently Asked Questions

What is in the GLOW peptide?

GHK-Cu, BPC-157, and TB-500. The name is a marketplace label, and the amount of each peptide varies by source.

What are the benefits of the GLOW peptide stack?

The claimed benefits are skin quality, tissue repair, and recovery. The strongest supporting evidence is for topical GHK-Cu and skin appearance; evidence for the injectable components is largely preclinical, and the combination itself has not been studied.

Is there an established GLOW peptide dosage?

No. There is no FDA-labeled dose and no clinical trial of the blend. Any dosing is prescriber-determined from each component's own evidence.

How is GLOW different from KLOW?

KLOW adds a fourth peptide, KPV, for its anti-inflammatory rationale. See our KLOW peptide guide.

Is the GLOW peptide legal to compound?

It depends on each component's status. In July 2026 FDA proposed not adding BPC-157 or TB-500 to the 503A Bulks List, and GHK-Cu was scheduled for PCAC review by February 2027. Check the FDA tracker for current status.